Amgen ($AMGN) investor dismisses Actelion as buyout target

Amgen ($AMGN) shareholder Invesco Ltd. isn't impressed with Swiss drugmaker Actelion as a buyout target for the company, said fund manager Derek Taner. Report

Suggested Articles

Gilead Sciences has found a new chief financial officer in an appointment that has mergers and acquisitions written all over it.

Pfizer's role as the hero in ramping up production of a chemo drug badly needed by pediatric oncologists is a turnabout for the drugmaker.

Johnson & Johnson is dealing with $2 billion in patent losses in 2019, but has 10 drugs growing at double-digit percentages, executives said Tuesday.